Valuation: Natera, Inc.

Market Cap 54.62B 48.76B 44.75B 40.71B 76.32B 5,171B 77.84B 534B 215B 2,729B 205B 201B 8,620B P/E 2026 *
-264x
P/E 2027 * -3,378x
Enterprise Value 53.53B 47.79B 43.86B 39.89B 74.8B 5,068B 76.29B 524B 211B 2,675B 201B 197B 8,449B EV / Sales 2026 *
18.4x
EV / Sales 2027 * 15.1x
Free-Float
97.25%
Yield 2026 *
-
Yield 2027 * -
1 day+2.82%
1 week-4.13%
Current month-4.93%
1 month-7.46%
3 months+45.68%
6 months+86.17%
Current year+71.93%
1 week 376.38
Extreme 376.375
436.19
1 month 376.38
Extreme 376.375
437.41
Current year 181
Extreme 181
437.41
1 year 181
Extreme 181
437.41
3 years 40.61
Extreme 40.61
437.41
5 years 26.1
Extreme 26.1
437.41
10 years 7.35
Extreme 7.35
437.41
Manager TitleAgeSince
Chief Executive Officer 47 2019-01-01
President 46 2023-08-31
Director of Finance/CFO 45 2017-01-31
Director TitleAgeSince
Chairman 53 2015-04-30
Director/Board Member 53 2006-12-31
Director/Board Member 47 2019-01-01
Date Insider Type Main position Quantity % Market Cap. Importance
10/15/26 Exercice

Founder

150,000 0.1041%
10/7/26 Don

Founder

-6,000 0.0042%
10/1/26 Sell

Chief Executive Officer

-1,273 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
+2.54%-4.13%+98.69%+821.55% 54.62B
+1.10%-2.35%+13.44%+26.67% 113B
+0.43%+4.14%+1.52%+102.99% 97.71B
+4.21%+1.17%-6.04%+82.74% 30.65B
+0.36%+7.99%+38.70%+70.12% 28.87B
-0.15%+3.48%+40.35%+87.45% 27.59B
+2.07%+4.20%+35.59%+397.20% 21.4B
-1.28%-5.43%-21.72%-16.73% 19.74B
-1.15%-1.02%-5.94%+29.77% 17.04B
+4.50%+18.19%+105.96% - 13.81B
Average +1.30%+0.99%+30.06%+177.97% 42.46B
Weighted average by Cap. +1.22%-0.82%+25.44%+179.16%

Financials

2026 *2027 *
Net sales 2.91B 2.6B 2.38B 2.17B 4.07B 276B 4.15B 28.48B 11.48B 145B 10.92B 10.69B 459B 3.52B 3.14B 2.88B 2.62B 4.92B 333B 5.01B 34.43B 13.88B 176B 13.2B 12.92B 555B
Net income -203M -181M -167M -151M -284M -19.24B -290M -1.99B -802M -10.16B -763M -747M -32.08B -8.5M -7.59M -6.97M -6.34M -11.88M -805M -12.12M -83.19M -33.53M -425M -31.91M -31.23M -1.34B
Net Debt -1.09B -972M -892M -811M -1.52B -103B -1.55B -10.65B -4.29B -54.39B -4.09B -4B -172B -1.4B -1.25B -1.15B -1.05B -1.96B -133B -2B -13.74B -5.54B -70.16B -5.27B -5.16B -222B
Projected Income Statement - Annual - Natera, Inc.
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
26-11-03 US$392.61 +3.61% 1,442,855
26-11-02 US$378.92 -8.54% 2,627,909
26-10-30 US$414.30 -4.98% 2,432,183
26-10-29 US$436.00 +2.73% 1,326,459
26-10-28 US$424.42 +3.31% 1,548,874
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
MarketScreener Ratings - Natera, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
378.92USD
Average target price
416.39USD
Spread / Average Target
+9.89%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Natera, Inc.
  1. Stock Market
  2. Stocks
  3. NTRA Stock